Atacand (correction)

In a story on the supplemental approval of AstraZeneca's angiotensin receptor blocker Atacand, the statement "I am just a bit concerned by the proposed labeling that I have seen....[It] seems to leave that door open, and once a door like that is open, it's going to be their job to walk through it and encourage people to use it that way" was incorrectly attributed to FDA Office of Drug Evaluation I Director Robert Temple (1"The Pink Sheet" Feb. 28, 2004, p. 3). The statement was made by Cardiovascular & Renal Drugs Advisory Committee member John Teerlink...